一种三小核仁RNA特征：SNORD15A、SNORD35B和SNORD60作为肾细胞癌的新型生物标志物。
A three-snoRNA signature: SNORD15A, SNORD35B and SNORD60 as novel biomarker for renal cell carcinoma.
作者信息
Zhang Yue, Shang Xiaoling, Yu Miao, Bi Zhao, Wang Kangyu, Zhang Qianru, Xie Li, Song Xianrang, Song Xingguo
机构信息
Department of Clinical Laboratory, Shandong Cancer Hospital and Institute, Shandong First Medical University, Shandong Academy of Medical Sciences, 440 Ji-Yan Road, Jinan, 250117, Shandong Province, PR China.
Shanghai Pudong New Area Center for Disease Control and Prevention, 3039 Zhangyang Road, Shanghai, China.
出版信息
Cancer Cell Int. 2023 Jul 13;23(1):136. doi: 10.1186/s12935-023-02978-8.
BACKGROUND
Accumulating evidence has confirmed the role of snoRNAs in a variety of cancer, but rare in renal cell carcinoma (RCC). This study aims to clarify the role of snoRNAs in RCC tumorigenesis and their potential as novel tumor biomarkers.
MATERIALS AND METHODS
The snoRNA expression matrix was obtained from the public TCGA and SNORic databases. SNORD15A, SNORD35B and SNORD60 were selected and validated by qPCR, then analyzed combined with related clinical factors using T-test and ROC curve.
RESULTS
All three snoRNAs: SNORD15A, SNORD35B and SNORD60 were significantly upregulated in cancer tissues compared to adjacent tissues from TCGA or FFPE detection. These three snoRNAs were also increased in urinary sediment (US) of RCC as well as the early-stage RCC patients compared with the healthy controls. In addition, RNase stability experiments confirmed their stable existence in US. Meanwhile, the ROC curve shows that SNORD15A, SNORD35B and SNORD60 could effectively distinguish RCC (AUC = 0.7421) and early-stage RCC (AUC = 0.7465) from healthy individuals.
CONCLUSION
SNORD15A, SNORD35B and SNORD60 were upregulated in tissues and US of RCC, serving as novel potential biomarkers for RCC diagnosis.
背景
越来越多的证据证实了小核仁RNA（snoRNAs）在多种癌症中的作用，但在肾细胞癌（RCC）中却很少见。本研究旨在阐明snoRNAs在RCC肿瘤发生中的作用及其作为新型肿瘤生物标志物的潜力。
材料与方法
从公共的TCGA和SNORic数据库中获取snoRNA表达矩阵。选择SNORD15A、SNORD35B和SNORD60并通过qPCR进行验证，然后使用T检验和ROC曲线结合相关临床因素进行分析。
结果
与来自TCGA或FFPE检测的相邻组织相比，所有三种snoRNAs：SNORD15A、SNORD35B和SNORD60在癌组织中均显著上调。与健康对照相比，这三种snoRNAs在RCC的尿沉渣（US）以及早期RCC患者中也有所增加。此外，核糖核酸酶稳定性实验证实了它们在US中的稳定存在。同时，ROC曲线显示SNORD15A、SNORD35B和SNORD60可以有效地区分RCC（AUC = 0.7421）和早期RCC（AUC = 0.7465）与健康个体。
结论
SNORD15A、SNORD35B和SNORD60在RCC的组织和US中上调，可作为RCC诊断的新型潜在生物标志物。
Zotero 插件